Anti-VEGF Treatment Strategies for Wet AMD

Over the past few years, antivascular endothelial growth factor (VEGF) therapy has become a standard treatment for neovascular age-related macular degeneration (AMD). During this time, treatment strategies have evolved from a monthly dosing schedule to individualized regimens. This paper will review...

Descripción completa

Detalles Bibliográficos
Autores principales: Kovach, Jaclyn L., Schwartz, Stephen G., Flynn, Harry W., Scott, Ingrid U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317200/
https://www.ncbi.nlm.nih.gov/pubmed/22523653
http://dx.doi.org/10.1155/2012/786870
_version_ 1782228527081324544
author Kovach, Jaclyn L.
Schwartz, Stephen G.
Flynn, Harry W.
Scott, Ingrid U.
author_facet Kovach, Jaclyn L.
Schwartz, Stephen G.
Flynn, Harry W.
Scott, Ingrid U.
author_sort Kovach, Jaclyn L.
collection PubMed
description Over the past few years, antivascular endothelial growth factor (VEGF) therapy has become a standard treatment for neovascular age-related macular degeneration (AMD). During this time, treatment strategies have evolved from a monthly dosing schedule to individualized regimens. This paper will review the currently available anti-VEGF agents and evidence-based treatment strategies.
format Online
Article
Text
id pubmed-3317200
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-33172002012-04-20 Anti-VEGF Treatment Strategies for Wet AMD Kovach, Jaclyn L. Schwartz, Stephen G. Flynn, Harry W. Scott, Ingrid U. J Ophthalmol Review Article Over the past few years, antivascular endothelial growth factor (VEGF) therapy has become a standard treatment for neovascular age-related macular degeneration (AMD). During this time, treatment strategies have evolved from a monthly dosing schedule to individualized regimens. This paper will review the currently available anti-VEGF agents and evidence-based treatment strategies. Hindawi Publishing Corporation 2012 2012-02-28 /pmc/articles/PMC3317200/ /pubmed/22523653 http://dx.doi.org/10.1155/2012/786870 Text en Copyright © 2012 Jaclyn L. Kovach et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Kovach, Jaclyn L.
Schwartz, Stephen G.
Flynn, Harry W.
Scott, Ingrid U.
Anti-VEGF Treatment Strategies for Wet AMD
title Anti-VEGF Treatment Strategies for Wet AMD
title_full Anti-VEGF Treatment Strategies for Wet AMD
title_fullStr Anti-VEGF Treatment Strategies for Wet AMD
title_full_unstemmed Anti-VEGF Treatment Strategies for Wet AMD
title_short Anti-VEGF Treatment Strategies for Wet AMD
title_sort anti-vegf treatment strategies for wet amd
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317200/
https://www.ncbi.nlm.nih.gov/pubmed/22523653
http://dx.doi.org/10.1155/2012/786870
work_keys_str_mv AT kovachjaclynl antivegftreatmentstrategiesforwetamd
AT schwartzstepheng antivegftreatmentstrategiesforwetamd
AT flynnharryw antivegftreatmentstrategiesforwetamd
AT scottingridu antivegftreatmentstrategiesforwetamd

Ejemplares similares